Due Diligence Resources

Always do an appropriate amount of due diligence research before making an investment of any kind. Here we have gathered some of the information that we found while researching the company ourselves. This is not by any means an exhaustive list, so make sure to look elsewhere as well.

If you find anything of interest that you think could be of use to someone else, feel free to submit it to dd at best stock to invest in 2020 dot com (written out as a normal email address, obviously!).

Here is a great in-depth comparison of the Dexcom G6 and the Eversense system from a user of both systems.

Stock Price Comparison to Competitors

Senseonics Holdings, Inc. (SENS), is currently trading around $0.85-$0.90 per share (as of this writing). Dexcom (DXCM) shares in 2009 were trading at $1.36 and are now trading over $200 (see chart below).  Had you invested $10,000 in Dexcom stock at $1.36, that investment would now be worth over $1.4 million. Dexcom paved the way for CGMs; Senseonics won’t take nearly as long to move into the market, as CGM’s are already accepted among doctors and diabetes patients. Now that Eversense is covered by Medicare (as of 1/1/20), and other insurance coming on board all the time, we expect adoption rates to ramp up quickly. We consider SENS to be a long term position, and there certainly will be price fluctuations in both directions on its way to getting to a multibillion dollar market cap, but it’s helpful to look at the history of a similar competitor. Over the long haul, those who held on to their shares and didn’t worry about short term movements have been handsomely rewarded!

Dexcom Stock Price 2009-2020

This is the latest academic research from the National Institute of Health comparing the Eversense with other CGMs: 

Current Diabetes Technology: Striving for the Artificial Pancreas

Intellectual Property

Patents owned by Senseonics:


Ownership– Follow the smart money

Use this website to look at SEC filings for all institutional owners and inside ownership of the company. Besides ownership, you can also access past company financials and other helpful info. Some sections require a paid subscription to view all information.


Partnership with Beta Bionics/ iLet Bionic Pancreas

iLet Bionic Pancreas is a wearable, autonomous system that leverages artificial intelligence (AI) and machine learning to deliver insulin and glucagon analogues for treating type 1 diabetes. Recently granted BTD (breakthrough designation by the FDA**)

Senseonics and Beta Bionics Partner on Development of the Bionic Pancreas System

Beta Bionics receives FDA Breakthrough Device Designation For the iLet(TM) Bionic Pancreas System